Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P394: Preoperative serum vedolizumab levels do not predict postoperative outcomes in inflammatory bowel disease (IBD)ECCO '18 Vienna
Year: 2018
Authors:

N. Lopez1, K. Zaghiyan1, G. Melmed1, D. McGovern1, A. Jain2, S. Targan1, P. Fleshner1*, C. Landers1

1Cedars-Sinai Medical Center, Los Angeles, USA, 2Prometheus Laboratories, San Diego, USA

P395: Dermatological reactions associated with anti–TNF therapy in inflammatory bowel disease- an 12 year experienceECCO '18 Vienna
Year: 2018
Authors:

A. Bhandare*, R. Diyar, J. Taylor, J.K. Limdi

Pennine Acute Hospitals Trust, Gastroenterology, Manchester, UK

P396: Pharmacokinetics, immunogenicity and clinical outcomes of golimumab from the PURSUIT PEDS ulcerative colitis study long-term (through week 126) extensionECCO '18 Vienna
Year: 2018
Authors:

J. Hyams1, C.D. O’Brien2, L. Padgett2, J. Rosh3, D. Turner4, G. Veereman5, A. Griffiths6, M.B. Heyman7, G. Wahbeh8, J. Adedokun2, R. Strauss2, D. Chan2, J. Lynch2*

1Connecticut Children’s Medical Center, Hartford, USA, 2Janssen Research and Development, LLC, Spring House, USA, 3Goryeb Children's Hospital/Atlantic Health, Pediatric Gastroenterology, Clinical Development and Research Affairs, Morristown, USA, 4The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, Jerusalem, Israel, 5Free University Brussels, Brussels, Belgium, 6The Hospital for Sick Children, University of Toronto, Toronto, Canada, 7University of California San Francisco, Gastroenterology Division, San Francisco, USA, 8Seattle Children's Hospital, Seattle, USA

P397: Effectiveness of vedolizumab (VDZ) for the induction of remission in inflammatory bowel disease (IBD): Results from the Spanish Eneida RegistryECCO '18 Vienna
Year: 2018
Authors:

M. Chaparro1,2,3,4*, A. Garre1,2,3,4, I. Alfaro4,5, M. Iborra4,6, P. Mesonero7, I. Vera Mendoza8, A. Rodríguez9, J. Miquel-Cusachs10, S. Riestra11, P. Navarro12, L. De Castro Parga13, C. González-Muñoza14, M. Rivero15, M. Mañosa4,16, L. Fernández Salazar17, N. Jiménez18, J. Guardiola19, J. Cabriada20, A. Gutiérrez Casbas4,21, B. Sicilia22, J.L. Pérez Calle23, M. Piqueras24, A. Algaba25, O. Roncero26, A. Bargallo27, E. Sainz28, J. Barrio29, X. Calvet4,30, A. García31, M. Llorente Barrio32, R. Llorente Poyatos33, P. Almela34, R. Madrigal35, A.J. Lucendo Villarín36, R. Pajares37, M. Van Domselaar38, J. Legido Gil39, J.P. Gisbert1,2,3,4

1Hospital Universitario de La Princesa, Gastroenterology Unit, Madrid, Spain, 2Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain, 3Universidad Autónoma de Madrid, Madrid, Spain, 4Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, 5Hospital Clínico y Provincial de Barcelona, Gastroenterology Unit, Barcelona, Spain, 6Hospital Universitario y Politécnico de La Fe, Gastroenterology Unit, Valencia, Spain, 7Hospital Universitario Ramón y Cajal, Gastroenterology Unit, Madrid, Spain, 8Hospital Universitario Puerta de Hierro, Gastroenterology Unit, Madrid, Spain, 9Hospital Universitario De Salamanca, Gastroenterology Unit, Salamanca, Spain, 10Hospital Universitario de Gerona Dr Josep Trueta, Gastroenterology Unit, Gerona, Spain, 11Hospital Universitario Central de Asturias, Gastroenterology Unit, Oviedo, Spain, 12Hospital Clínico Universitario de Valencia, Gastroenterology Unit, Valencia, Spain, 13Complejo Hospitalario Universitario de Vigo, Gastroenterology Unit, Vigo, Spain, 14Hospital de La Santa Creu i Sant Pau, Gastroenterology Unit, Barcelona, Spain, 15Hospital Universitario de Marqués de Valdecilla, Gastroenterology Unit, Santander, Spain, 16Hospital Universitario Germans Trias i Pujol, Gastroenterology Unit, Badalona, Spain, 17Hospital Clínico Universitario de Valladolid, Gastroenterology Unit, Valladolid, Spain, 18Hospital General Universitario de Elche, Gastroenterology Unit, Elche, Spain, 19Hospital Universitario de Bellvitge, Gastroenterology Unit, Hospitalet de Llobregat, Spain, 20Hospital de Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain, 21Hospital General Universitario de Alicante, Gastroenterology Unit, Alicante, Spain, 22Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain, 23Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Alcorcón, Spain, 24Consorci Sanitari Terrassa, Gastroenterology Unit, Tarrasa, Spain, 25Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Fuenlabrada, Spain, 26Complejo Hospitalario la Mancha Centro, Gastroenterology Unit, Alcázar de San Juan, Spain, 27Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology Unit, Sant Joan Despí, Spain, 28Hospital Universitario Arnau de Vilanova, Gastroenterology Unit, Lérida, Spain, 29Hospital Universitario Rio Hortega, Gastroenterology Unit, Valladolid, Spain, 30Consorcio Corporación Sanitaria Parc Taulí, Gastroenterology Unit, Sabadell, Spain, 31Hospital Virgen de La Victoria, Gastroenterology Unit, Málaga, Spain, 32Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain, 33Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain, 34Hospital General Universitario de Castellón, Gastroenterology Unit, Castellón, Spain, 35Complejo Hospitalario de Palencia, Gastroenterology Unit, Palencia, Spain, 36Hospital Público General de Tomelloso, Gastroenterology Unit, Tomelloso, Spain, 37Hospital Universitario Infanta Sofía, Gastroenterology Unit, San Sebastián de los Reyes, Spain, 38Hospital Universitario de Torrejón, Gastroenterology Unit, Torrejón de Ardoz, Spain, 39Hospital General de Segovia, Gastroenterology Unit, Segovia, Spain

P398: Cannabis induces clinical and endoscopic improvement in moderately active ulcerative colitis (UC)ECCO '18 Vienna
Year: 2018
Authors:

T. Naftali1,2*, L. Bar Lev Schlieder3, F. Sklerovsky Benjaminov1,2, I. Lish2,4, J. Hirsch4, F.M. Konikoff1,2

1Meir medical center, Gastroenterology, Kfar Saba, Israel, 2Tel Aviv University Sackler School of Medicine, Internal Medicine, Tel Aviv, Israel, 3Bar Ilan University, Behavioural Sciences, Tel Aviv, Israel, 4Meir Medical Center, Department of Gastroenterology and Hepatology, Kfar Saba, Israel

P399: Vedolizumab therapy results in reduced hospitalisation and steroid use over 1-year: Results from the Scottish vedolizumab consortiumECCO '18 Vienna
Year: 2018
Authors:

N. Plevris1*, C.S. Chuah1, R. Allen2, P. Baker2, P. Brennan3, A. Churchhouse1, E. Donoghue4, D. Gaya2, H. Jafferbhoy5, P. Jenkinson1, G. Jones1, J. Macdonald2, M. MacMaster2, C. Mowat3, G. Naismith6, L. Potts7, E. Saffouri2, J.P. Seenan2, A. Sengupta5, P. Shasi3, J. Todd3, J. Veryan2, A. Watson8, D. Watts4, I. Arnott1, C. Lees1, M. Groome3 M. Calvo1*, I. Alonso2, K. Villa1,3, V. Matallana1, Y. González Lama1, M.I. Vera1, A. Sanchez Movilla2, P. Calvo2, A. Royuela4, L. Abreu1

1NHS Lothian, Gastroenterology, Edinburgh, UK, 2NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, UK, 3NHS Tayside, Gastroenterology, Dundee, UK, 4NHS Forth Valley, Gastroenterology, Forth Valley, UK, 5NHS Fife, Gastroenterology, Kirkcaldy, UK, 6NHS Lanarkshire, Gastroenterology, Lanarkshire, UK, 7NHS Highlands, Gastroenterology, Inverness, UK, 8NHS Highlands, Colorectal Surgery, Inverness, UK 1Hospital Universitario Puerta de Hierro Majadahonda, IBD Unit, Gastroenterology and Hepatology Department, Majadahonda, Madrid, Spain, 2Hospital Universitario Puerta de Hierro Majadahonda, IBD Unit, Colorectal Surgery Department., Majadahonda, Madrid, Spain, 3Centro de Gastroenterologia, Ciudad Sanitaria Dr. Luis E. Aybar, IBD Unit. Gastroenterology and Hepatology Department, Santo Domingo, Spain, 4Hospital Universitario Puerta de Hierro Majadahonda, Clinical Biostatistics Unit, Biomedical Sciences Research Institute Puerta de Hierro, Majadahonda, Madrid, Spain

P401: Reduction of dosing intervals is the preferable dose optimisation strategy for infliximab to suppress formation of anti-drug antibodiesECCO '18 Vienna
Year: 2018
Authors:

W. Reinisch1*, A. Eser1, S. Schreiber2, H. Kim3, D. Mould4

1Medical University of Vienna, Department of Internal Medicine III, Gastroenterology and Hepatology, Vienna, Austria, 2Christian Albrechts University Kiel, Department of General Internal Medicine I; Institute of Clinical Molecular Biology, Kiel, Germany, 3Celltrion Healthcare Co. Ltd., Incheon, South Korea, 4Projections Research, Inc., Projections Research Inc., Phoenixville, USA

P402: Interstitial and granulomatous lung disease in inflammatory bowel disease patientsECCO '18 Vienna
Year: 2018
Authors:

E. Eliadou1*, J. Moleiro2, D.G. Ribaldone3, M. Astegiano3, K. Rothfuß4, C. Taxonera5, B. Verstockt6, F. Ghalim7, F. Carbonnel7, S. Festa8, A. Berrozpe9, L. Maia10, E. Savarino11, P. Ellul12, E. Zagorowicz13, S. Vavricka14, M. Calvo15, I. Koutroubakis16, F. Hoentjen17, L. Fernández Salazar18, F. Callela19, F. Cañete Pizarro20, K. Soufleris21, E. Sonnenberg22, M. Cavicchi23, G. Fiorino24,25

1Manchester Royal Infirmary, Department of Gastroenterology, Manchester, UK, 2Instituto Portugues de Oncologia de Lisboan Francisco Gentil, Lisboa, Portugal, 3Gastroenterologia-U, Città della Salute e della Scienza di Torino, Turin, Italy, 4Robert-Bosch Hospital, Gastroenterology Department, Stuttgart, Germany, 5Servicio Aparato Digestivo, Hospital Clínico San Carlos, IBD unit, Madrid, Spain, 6University Hospitals Leuven, Gastroenterology Department, Leuven, Belgium, 7Kremlin Bicêtre Hospital, AP-HP, University Paris Sud, Gastroenterology Department, Paris, France, 8Ospedale S. Filippo Neri, Gastroenterology Department, Rome, Italy, 9Bellvitge's hospital, Gastroenterology Department, Barcelona, Spain, 10Centro Hospitalar do Porto, Gastroenterology Department, Porto, Portugal, 11University of Padua, Padua, Italy, 12Mater Dei Hospital, Msida, Malta, 13The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Gastroenterology Department, Warsaw, Poland, 14Triemli Hospital, Zurich, Switzerland, 15Hospital Universitario Puerta de Hierro Madrid, Madrid, Spain, 16University of Crete, Heraklion, Greece, 17Radboud University Medical Center, Nijmegen, The Netherlands, 18Clínico Universitario de Valladolid, Valladolid, Spain, 19UOC Gastroenterologia, Ospedale San Giuseppe, Florence, Italy, 20Hospital Universitari Germans Trias i Pujol in Badalona, Barcelona, Spain, 21Theagenion Cancer Hospital of Thessaloniki, Thessaloniki, Greece, 22Charité-Universitätsmedizin Berlin, Berlin, Germany, 23Clinique de Bercy, Paris, France, 24RCCS Istituto Clinico Humanitas, Gastroenterology Department, Rozzano, Milan, Italy, 25For ECCO CONFER Steering Committee, Vienna, Austria

P403: Treatment naïve newly diagnosed patients with Crohn's disease have microbial dysbiosis correlated with disease activity and faecal calprotectin—results from a prospective inception cohortECCO '18 Vienna
Year: 2018
Authors:

H. Yanai1,2*, I. Goren3,4, L. Reshef5, L. Godny1,2, K. Yadgar1, K. Zonenesain1, I. Dotan2,3

1IBD Center, Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel, 2Sackler Faculty of Medicine, Tel Aviv Israel, Tel Aviv, Israel, 3Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel, 4Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 5Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel

P404: Development of anti-drug antibodies among those treated with adalimumab and ABP 501 and its impact on serum drug concentration in randomised controlled studiesECCO '18 Vienna
Year: 2018
Authors:

V. Chow*, A. Kaliyaperumal, N. Zhang, J. Miller, D. Mytych, M. Starcevic Manning, I. Wala, H. Wang, E. Krishnan

Amgen Inc., Biosimilars, Thousand Oaks, USA

P405: 5-ASA prescription trends over time in inflammatory bowel disease 1996 to 2015–A UK population-based studyECCO '18 Vienna
Year: 2018
Authors:

V. Jairath1,2*, S. Hokkanen3, L. Guizzetti2, N. Boxall3, S. Campbell-Hill4, H. Patel4

1Western University, Department of Medicine, London, Ontario, Canada, 2Robarts Clinical Trials Inc., London, Ontario, Canada, 3IQVIA, London, UK, 4Takeda International–UK Branch, London, UK

P406: Malnutrition during hospitalisation for acute severe IBD is associated with increased risk of relapseECCO '18 Vienna
Year: 2018
Authors:

K. Kulmala1*, J. Björk2, S. Andersson3, A.-S. Backman1,2, C.R.H. Hedin2, F. Bresso2

1Karolinska Institutet, Department of Medicine, Solna, Unit of Internal Medicine, Stockholm, Sweden, 2Karolinska University Hospital, Gastroenterology Unit, Patient Area Gastroenterology, Dermatovenereology and Rheumatology, Stockholm, Sweden, 3Karolinska University Hospital, Department of Clinical Nutrition, Stockholm, Sweden

P407: Faecal calprotectin predicts sustained treatment response of infliximab induction therapy superior to C-reactive protein and clinical activity scores in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

P.M. Hellström1*, M. Lonnkvist2, H.O. Diaz Tartera1, R. Befrits2, M. Holst3

1Uppsala University, Medical Sciences, Uppsala, Sweden, 2Karolinska Institutet, Medicine, Stockholm, Sweden, 3Karolinska Institutet, Women's and Children's Health, Stockholm, Sweden

P408: Intestinal failure in Crohn’s disease: A case–control studyECCO '18 Vienna
Year: 2018
Authors:

M. Soop1*, A. Bond2, E. Nixon2, A. Teubner1, A. Abraham1, G. Carlson1, S. Lal2

1Irving National Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Surgery, Manchester, UK, 2Irving National Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Gastroenterology, Manchester, UK

P409: Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: Results from a real-world observational studyECCO '18 Vienna
Year: 2018
Authors:

Y. Suzuki1*, T. Hagiwara2, M. Kobayashi2, K. Morita2, T. Shimamoto2, T. Hibi3

1Toho University, Sakura Medical Center, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Sakura-shi, Chiba, Japan, 2AbbVie GK, Tokyo, Japan, 3Kitasato University Kitasato Institute Hospital, IBD Centre, Tokyo, Japan

P410: Has body composition any effect on thiopurine level in IBD?ECCO '18 Vienna
Year: 2018
Authors:

Á. Milassin1*, K. Szántó1, A. Fábián1, R. Bor1, K. Farkas1, A. Bálint1, M. Rutka1, I. Földesi2, A.L. Szijártó3, Z.A. Mezei4, T. Bubán5, F. Nagy1, Z. Szepes1, T. Molnár1, K. Palatka6

1University of Szeged, 1st Department of Internal Medicine, Szeged, Hungary, 2University of Szeged, Institute of Laboratory Medicine, Szeged, Hungary, 3University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, 4University of Debrecen, Department of Laboratory Medicine, Debrecen, Hungary, 5University of Debrecen, Department of Internal Medicine, Debrecen, Hungary, 6University of Debrecen, 2nd Department of Internal Medicine, Debrecen, Hungary

P411: Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease centre: Accessibility, resource utilisation and outcomesECCO '18 Vienna
Year: 2018
Authors:

S. Restellini1,2*, I. Morin1, Z. Kurti3, T. Bessissow1, W. Afif1, G. Wild1, E. Seidman1, A. Bitton1, P.L. Lakatos1,3

1McGill University Health Center, Department of Gastroenterology, Montreal, Canada, 2Geneva’s University Hospitals and University of Geneva, Division of Gastroenterology and Hepatology, Geneva, Switzerland, 3Semmelweis University, First Department of Medicine, Budapest, Hungary

P412: White cell count (WCC) and mean corpuscular volume (MCV) as surrogate markers for thiopurine monitoring in inflammatory bowel disease (IBD) treatment: A single-centre experienceECCO '18 Vienna
Year: 2018
Authors:

B. Christopher*, K. Altamimi, N. Campbell, R. Rynne-Lyons, A. Alakkari, A. O'Connor, D. McNamara, N. Breslin, B. Ryan

Adelaide and Meath, Incorporating National Childrens' Hospital, Tallaght, Department of Gastroenterology, Tallaght Hospital, Dublin and Department of Clinical Medicine, TCD, Dublin, Ireland

P413: Relative frequency of relapses in patients with ulcerative colitis and Crohn's disease treated with mesenchymal stromal cells: Five-years of follow-upECCO '18 Vienna
Year: 2018
Authors:

N. Fadeeva1*, O. Knyazev1, A. Kagramanova1, A. Babayan1, A. Lishchinskaya1, I. Ruchkina1, A. Konoplyannikov2, A. Parfenov1

1Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, 2Medical Radiological Scientific Center, Department of Stem Cells Therapy, Obninsk, Russian Federation

P414: Loss of response to anti-TNF in inflammatory bowel disease in a Portuguese centreECCO '18 Vienna
Year: 2018
Authors:

M. Sousa*, A.P. Silva, A. Rodrigues, J. Rodrigues, J. Silva, C. Gomes, L. Proença, J. Carvalho

Centro Hospitalar de Vila Nova de Gaia e Espinho, Vila Nova de Gaia, Portugal